VAXART INC (VXRT)
US92243A2006 - Common Stock
Vaxart Announces Positive Results for Its Bivalent Norovirus Vaccine Candidate in Lactating Mothers
Antibody rise observed in lactating mothers and in their breast milk Long-term goal is to provide protection to infants through passive antibody...
Election Year Encore: Can 2020’s Top 7 Stock Winners Repeat Their Performance in 2024?
These seven companies were the top 2020 stocks. After their glory years have faded, they are looking to turn their fortunes around.
Vaxart to Present at World Vaccine Congress Washington 2024 on April 3
SOUTH SAN FRANCISCO, Calif., March 27, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that Dr. Sean Tucker, Founder and Chief...
Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., March 20, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) (the “Company” or “Vaxart”) today announced that the...
VXRT Stock Earnings: Vaxart Beats EPS, Beats Revenue for Q4 2023
VXRT stock results show that Vaxart beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2023.
VXRT Stock Earnings: Vaxart Beats EPS, Beats Revenue for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Vaxart (NASDAQ:VXRT) just reported results for the fourth quarter of 2023.Vaxar...
Vaxart Provides Business Update and Reports Full Year 2023 Financial Results
Significant progress made in preparing for a Phase 2b study evaluating Vaxart’s oral pill XBB COVID-19 vaccine against an approved mRNA vaccine comparator ...
Vaxart to Host Full Year 2023 Business Update and Financial Results Conference Call on March 14
Conference call to begin at 4:30 p.m. ET...
Vaxart, Inc. Appoints Steven Lo as President, Chief Executive Officer, and Director
Michael J. Finney, Ph.D. to Continue as Chairman of the Board of Directors SOUTH SAN FRANCISCO, Calif., March 06, 2024 (GLOBE NEWSWIRE) -- Vaxart,...
Vaxart Announces Publication in Vaccines of Non-Human Primate Preclinical Data Demonstrating Its Next-Generation Vaccine Candidates Elicit Mucosal and Systemic Immunogenicity and Reduce Viral Shedding after SARS-CoV-2 Challenge
— Data served as foundation for current vaccine candidate for planned Phase 2 research — Vaxart vaccine candidates elicited strong antigen-specific...
Vaxart stock spikes as B. Riley upgrades to Buy (NASDAQ:VXRT)
Vaxart (VXRT) stock surged as B. Riley upgraded the vaccine developer to Buy from Neutral citing a $9M funding it recently received from BARDA. Read more here.
Vaxart gets BARDA funding for Phase 2 study of COVID-19 pill vaccine (VXRT)
Vaxart (VXRT) has been awarded funding by the US government for a large-scale Phase 2b study for its orally administered COVID-19 vaccine candidate. Read more here.
Vaxart Receives $9.27 Million BARDA Project NextGen Award to Prepare for Phase 2b Clinical Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate
- 10,000-subject Phase 2b study would evaluate Vaxart’s next generation oral pill XBB COVID-19 vaccine against an approved mRNA vaccine comparator - -...
Vaxart to buyback $10M worth stock, key person steps down (NASDAQ:VXRT)
Vaxart (VXRT) CEO Andrei Floroiu has resigned, and Michael J. Finney, Ph.D., the Chair of the Board, will serve as interim CEO during the transition.
Vaxart Announces $10.0 Million Registered Direct Offering with RA Capital Management
SOUTH SAN FRANCISCO, Calif., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that it has entered into a common stock...
Vaxart, Inc. Announces Management Change
Chief Executive Officer Andrei Floroiu Resigns Chair Michael J. Finney, Ph.D. to Serve as Interim Chief Executive Officer SOUTH SAN FRANCISCO, Calif.,...
Bank of America favorable on SMID-cap biotechs into 2024
Biotech stocks gain as Bank of America takes a more positive view on SMID-cap stocks and specialty pharma. Read more here.
Vaxart Announces Last Subject Dosed in Phase 1 Trial of Its Norovirus Vaccine Candidate in Lactating Mothers
On track to report topline data by the end of 2024 SOUTH SAN FRANCISCO, Calif., Dec. 21, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today...
Vaxart Provides Business Update and Reports Third Quarter 2023 Financial Results
Norovirus challenge study topline results indicate the potential of Vaxart’s oral pill vaccine candidate to reduce rates of norovirus infection, norovirus...
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
It's time to dive into the biggest pre-market stock movers as we start the trading week on Monday with the hottest coverage!
Vaxart to Present at World Vaccine Congress Europe 2023 on October 18-19
SOUTH SAN FRANCISCO, Calif., Oct. 11, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that Dr. Sean Tucker, Founder and Chief...
3 Biotech Blockbusters to Turn $5,000 Into $50,000
These transformative early-stage biotech stocks can deliver triple-digit upside if their key milestones are achieved on time.
Vaxart Provides Business Update and Reports Second Quarter 2023 Financial Results
On track to report topline data from Phase 2 GI.1 norovirus vaccine challenge study in Q3 2023 Cash runway extended into Q3 2024 Conference call today at...
Vaxart succeeds in mid-stage trial for oral norovirus shot
Vaxart (VXRT) said Thursday that a Phase 2 trial for its oral norovirus shot met all main goals, leading to strong immune responses across all doses. Read more here.
Vaxart Stockholders Approve All Four Proposals in the 2023 Proxy Statement
SOUTH SAN FRANCISCO, Calif., June 26, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today held its Annual Meeting of Shareholders in a...
Vaxart Encourages All Stockholders of Record as of April 28, 2023 to Vote by June 25, 2023, at 11:59 p.m. ET
SOUTH SAN FRANCISCO, Calif., June 21, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today encourages its stockholders of record on April 28, 2023,...